Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Citius Pharmaceuticals filings document a Nasdaq-listed biopharmaceutical issuer with common stock registered on The Nasdaq Capital Market and a majority-owned oncology subsidiary. Recent Form 8-K disclosures cover material definitive agreements, registered direct offerings, pre-funded warrants, common warrants, unregistered equity securities and amendments to a promissory note involving Citius Oncology.
The company’s regulatory filings also record LYMPHIR commercial updates, international shipment disclosures, investigator-initiated oncology study announcements, and other material events incorporated through press-release exhibits. Proxy materials document annual meeting matters, including director elections, auditor ratification and shareholder voting results.
Citius Pharmaceuticals, through its subsidiary Citius Oncology, reported early Phase 1 data on LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. In 21 efficacy-evaluable patients from a 25-patient study, 48% achieved clinical benefit, with a median progression-free survival of 20.5 months in this subgroup.
The heavily pre-treated population had a median of five prior therapies, and more than half had prior PD-1 or PD-L1 treatment. Investigators described durable responses and manageable tolerability, including activity in relapsed or refractory endometrial cancer. The study was investigator-initiated, open-label, and dose-escalation, and was not designed or powered to prove efficacy.
The company emphasized that LYMPHIR’s use in gynecologic malignancies remains investigational and outside its FDA-approved indication in cutaneous T-cell lymphoma. A Phase 2 expansion study is being planned, while ongoing translational work aims to identify biomarkers and refine future development strategies for this chemo-free immunomodulatory approach.
Citius Pharmaceuticals registers up to 5,431,473 shares of common stock issuable upon exercise of warrants. This preliminary prospectus covers (i) up to 5,076,143 shares issuable upon exercise of Common Warrants and (ii) up to 355,330 shares issuable upon exercise of Placement Agent Warrants, offered for resale by the selling stockholders. The company will not receive proceeds from resales, but could receive up to $4,803,000.81 in the aggregate if all warrants are exercised for cash; such proceeds are allocated to working capital. The prospectus discloses Nasdaq bid-price noncompliance notice and recent financings including a registered direct offering that raised approximately $4.5 million net proceeds.
Citius Pharmaceuticals reported fiscal second quarter 2026 results, highlighted by initial LYMPHIR commercial traction and significantly higher operating losses. Revenue reached $1,667,298 for the quarter and $5,611,409 for the first half, compared with no revenue a year earlier, generating $4,493,323 in gross profit.
Operating expenses rose sharply, driving an operating loss of $32,194,786 and a net loss attributable to common stockholders of $29,451,925 for the first half. The company ended March 31, 2026 with $4,590,174 in cash and cash equivalents and total assets of $132,540,579. Management highlighted LYMPHIR’s launch progress, including strong payer coverage, and recent financings, including a $5 million registered direct offering and up to $36.5 million in Citius Oncology debt and equity commitments.
Citius Pharmaceuticals reported its first meaningful LYMPHIR sales but remains deeply unprofitable and capital constrained. Net revenue reached $5.6M for the six months ended March 31, 2026, generating gross profit of $4.5M. However, total operating expenses of $45.7M, including large general and administrative costs and amortization of in-process R&D, led to a net loss of $37.5M and a loss per share of $1.34.
Cash and cash equivalents were $4.6M with negative working capital of about $23.3M, and operating activities used $14.3M of cash over six months. The company recognized a $3.8M gain from selling New Jersey net operating losses but also recorded about $20.1M of termination-related charges and a $19.7M contract cancellation fee after its LYMPHIR bulk drug substance manufacturer ended the supply agreement and exited microbial production.
Management’s going concern note states there is substantial doubt about Citius’s ability to continue beyond November 2026 without new funding. Subsequent events include a $5.0M registered direct offering at $0.985 per share, approximately $11.5M of Citius Oncology warrant-inducement proceeds, and a loan facility of up to $25.0M for Citius Oncology bearing at least 12.75% interest. Both Citius Pharma and Citius Oncology also received Nasdaq notices for minimum bid-price deficiencies.
Citius Pharmaceuticals, Inc. entered into a Third Amendment to a promissory note with its majority-owned subsidiary, Citius Oncology, Inc., originally issued on August 16, 2024 in the principal amount of $3,800,111. The amendment ties repayment so that the entire unpaid principal is due 91 days after Citius Oncology’s senior debt is fully repaid and its related loan and security agreement is terminated. It removes prior maturity triggers linked to capital raises, new debt or equity issuances, or royalty-backed monetizations, and bars cash prepayments before the new maturity date. The amendment also adds a voluntary feature allowing the Company, with Citius Oncology’s approval, to convert some or all principal into common stock at a $0.90 per share conversion price.
Citius Pharmaceuticals, Inc., through its majority-owned subsidiary Citius Oncology, Inc., reports the first international shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe via a regional distribution partner. LYMPHIR will be provided to eligible patients through Named Patient Programs under local regulations, expanding access beyond the United States.
The filing also notes, by reference, a previously closed registered direct offering of common stock and a concurrent private placement of pre-funded, common, and placement agent warrants. LYMPHIR is an FDA-approved targeted immune therapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and carries a boxed warning for capillary leak syndrome along with detailed safety and use information.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals entered into a registered direct offering and concurrent private placement with institutional investors. The company sold 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 and $0.9849, respectively, plus unregistered warrants to purchase up to 5,076,143 shares at $0.86.
Gross proceeds were approximately $5.0 million, with expected net proceeds of about $4.5 million after fees. Citius plans to use the funds to support the commercialization of LYMPHIR™, advance development of its product candidates, and for general corporate purposes.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.
Citius Pharmaceuticals, Inc. reported results from its 2026 Annual Meeting of stockholders. Shareholders elected seven directors, including Leonard Mazur and Myron Holubiak, to one-year terms ending at the 2027 annual meeting or until successors are elected and qualified.
Stockholders also ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 8,593,946 shares voting for, 855,866 against and 673,867 abstaining, and no broker non-votes reported on this item.